Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Crosses Below 50-Day Moving Average – Here’s Why

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) crossed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $15.46 and traded as low as $14.99. Ascentage Pharma Group International shares last traded at $15.00, with a volume of 7,313 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on AAPG shares. BTIG Research restated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. JPMorgan Chase & Co. lowered their price target on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a report on Thursday, October 8th. Citigroup began coverage on Ascentage Pharma Group International in a report on Wednesday, October 14th. They set a “buy” rating and a $46.00 price target for the company. William Blair initiated coverage on Ascentage Pharma Group International in a research report on Friday, October 16th. They set an “outperform” rating for the company. Finally, Citizens Jmp began coverage on shares of Ascentage Pharma Group International in a report on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and eleven have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $43.44.

Ascentage Pharma Group International Stock Down 3.2%

The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The stock has a 50 day moving average price of $15.46 and a two-hundred day moving average price of $19.72.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million during the quarter. As a group, research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 EPS for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.